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Introduction: Biologic therapies have proven efficacious for patients with moderate-to-severe 
psoriasis. However, their economic value compared with standard of care in Italy has not been 
explored. This study estimates the cost-effectiveness of intermittent therapy with etanercept 
in patients with moderate-to-severe plaque-type psoriasis in comparison with nonsystemic 
therapy in Italy.
Methods: This study employs cost–utility analysis using a Markov model adapted from the 
British “York model”. It compares the cost per quality-adjusted life-year (QALY) of intermittent 
etanercept (25 mg twice weekly) versus nonsystemic therapy. Data on efficacy and changes in 
quality of life were derived from three etanercept clinical trials. Direct costs of treating psoriasis 
patients, including hospitalizations and dermatology clinic visits, were taken from an Italian 
cost-of-illness study. Extrapolations were made to evaluate the cost-effectiveness of intermittent 
etanercept versus nonsystemic therapy over a period of ten years.
Results: For the group of patients with moderate and severe plaque psoriasis (initial Psoriasis 
Area and Severity Index [PASI  10]) the incremental cost-effectiveness ratio (ICER) for 
etanercept compared with nonsystemic therapy was  33,216/QALY; for the group of patients 
with severe psoriasis (PASI  20), the ICER was  25,486/QALY.
Conclusions: Within the Italian health care system, intermittent etanercept is a cost-effective 
therapeutic option compared with nonsystemic therapy for the group of patients with moderate 
and severe plaque psoriasis. For patients with PASI  20, cost-effectiveness of etanercept is 
even greater.
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Introduction
Psoriasis is a common inflammatory skin disorder affecting between 0.5% and 4.6% 
of the world population; the most common form is plaque-type psoriasis occurring 
in more than 80% of cases.1 Psoriasis is a chronic disease that can be physically and 
emotionally debilitating and is associated with profoundly impaired quality of life.2 
Because of its chronic nature, it can require lifelong symptom management.
Treatments available for the relief of moderate-to-severe psoriasis include 
photochemotherapy (PUVA) and systemic agents such as ciclosporin, methotrexate, 
and retinoids. Although effective, these therapies are associated with considerable 
toxicity which limits their long-term use.
In recent years, a better understanding of the immunopathogenesis of psoriasis 
has led to the development of more targeted biological drugs, capable of neutralizing 
specific components of the immune system responsible for the inflammatory response. ClinicoEconomics and Outcomes Research 2009:1 54
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So far, the role of the biologics, namely anti-T-cell agents and 
inhibitors of tumor necrosis factor-alpha (TNF-α), has been 
limited given the relative lack of data on long-term efficacy 
and safety3 and also the fact that in terms of drug acquisition 
they are costlier than conventional therapies. Some of these 
agents have been evaluated for longer periods recently and 
their efficacy and safety profiles suggest that they are likely 
to offer an alternative treatment strategy with the possibility 
of long-term continuous therapy, which may lead to better 
disease control and improved quality of life.4
Evidence is emerging that psoriasis may be associated 
with metabolic syndromes including insulin resistance, 
obesity, dyslipidemia, and hypertension. Consequently 
patients may be at a higher risk for cardiovascular events. 
Since the relationship between psoriasis and comorbidities 
such as metabolic syndrome and cardiovascular disease is 
likely to be linked to the underlying chronic inflammatory 
nature of psoriasis,5 biological agents may become central 
to the future clinical management of psoriasis and related 
comorbidities. A better understanding of the cost-effectiveness 
of biological agents is thus desirable. At present, three biologic 
therapies, etanercept (Enbrel),6 infliximab (Remicade),7 and 
adalimumab (Humira),8 are licensed for the treatment of 
moderate-to-severe psoriasis in Italy.
In our study we have undertaken a cost–utility analysis 
of etanercept, a human soluble recombinant TNF receptor 
protein, indicated, similarly to the other biologic agents, 
for the treatment of moderate-to-severe psoriasis in adults 
who failed to respond to, or who have a contraindication to, 
or are intolerant to other systemic therapy. Data on efficacy 
and safety of etanercept over 12 and 24 weeks have been 
demonstrated in phase III clinical trials.9 Our aim is to 
help better delineate the cost-effectiveness of etanercept 
compared with nonsystemic therapy by extrapolating its 
efficacy and costs over a 10-year time horizon using a 
Markov model.
Material and methods
Description of the model
To estimate the longer-term health effects and costs of 
treatment with intermittent etanercept, a Markov model 
was developed based on the “York Model” created by the 
CRD/CHE Technology Assessment Group for the UK.10 
The latter was also used by Lloyd and colleagues in their 
economic evaluation of etanercept in the management of 
chronic plaque psoriasis.11 Specifically, we simulated the 
use of etanercept 25 mg twice weekly for the treatment of 
moderate-to-severe plaque-type psoriasis compared with 
nonsystemic (ie, topical) therapy. The model was run for 
10 years. The key input parameters on which the model is 
based were obtained from three etanercept clinical trials.9,12,13 
Direct costs of treating psoriasis patients, including hospi-
talizations and dermatology clinic visits, were taken from an 
Italian cost-of-illness study.14
To  evaluate  cost-effectiveness,  the  incremental 
cost-effectiveness ratio (ICER) was used. When the value 
of a new therapeutic option needs to be assessed, the ICER 
provides the additional resources that have to be used to 
achieve the additional benefit: ICER is the difference in cost 
(C) divided by the difference in effect (E) between two 
alternatives. In this analysis direct cost and effectiveness of 
intermittent etanercept were compared with direct cost and 
effectiveness of nonsystemic therapy.
  ICER
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=
⋅
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The present evaluation is a cost–utility analysis, a form 
of economic study in which interventions leading to different 
consequences in terms of quantity and quality of life are 
expressed as utilities (eg, a number summarizing the value 
patients attach to their current state of health). The quality-
adjusted life-year (QALY)15 was used as utility measure and 
intermittent etanercept was compared with nonsystemic 
therapy in terms of cost per QALY. QALYs were determined 
based on the time trade-off (TTO) method.
Structure of the model
The Markov model is based on 12-week treatment periods 
spanning 10 years. After each cycle, patients pass through 
different categories. There is an initial phase when patients 
with intermittent therapy receive etanercept 25 mg twice 
weekly and are then evaluated in terms of clinical response. 
Three events are possible:
1.  Psoriasis Area and Severity Index (PASI) response 50%, 
considered as treatment failure → Nonresponder
2.  An improvement between 50% and 74% in PASI over 
baseline → Partial responder
3.  An improvement of at least 75% in PASI over baseline 
(PASI 75) → Full responder
Patients failing to achieve 50% in PASI after a 12-week 
cycle (1) are classified as “treatment nonresponders,” they 
remain in this category for the remaining time period and 
receive no further treatment with etanercept.
Patients experiencing an improvement between 50% and 
74% in PASI (2) are eligible for re-treatment with etanercept 
25 mg twice weekly for another 12 weeks. They are then ClinicoEconomics and Outcomes Research 2009:1 55
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re-evaluated and those reaching an improvement of PASI 
of least 75% are classified as “full responders” and enter 
the category “remission”, where they temporarily suspend 
etanercept use. For those failing to reach this target at the end 
of the second cycle (24 weeks), treatment with etanercept is 
permanently discontinued.
Patients achieving PASI 75 after the first 12 weeks of 
intermittent etanercept (3) enter the category “remission”. 
When patients in remission experience relapse (PASI worsens 
by 50% of the treatment effect) they are re-treated, PASI 
is determined again, and the patient is assigned to the new 
corresponding category.
Patients receiving basal treatment (ie, topical treatment 
only) continue on this therapy for the entire time period. 
Mortality was not taken into account.
A graphic description of the model is shown in Figure 1. 
Figure 2 illustrates the distribution of patients receiving 
intermittent etanercept derived from the extrapolation among 
the different categories over the 10-year time frame.
The model allows discounting of both costs and utilities; 
a discount rate of 3.5% yearly was calculated for costs and 
utilities in the sensitivity analyses.
Modeling was undertaken using the statistical package, 
Decision Data Tree (version 4.0; TreeAge Software Inc., 
Williamstown, MA, USA).
Characteristics of the model for italy
Probabilities of transition were calculated based on the 
disease severity classes. Specifically, for patients with 
moderate psoriasis (10  PASI  20), a mean PASI score of 
15 was considered, whereas for patients with a severe form 
(PASI  20), the score was approximated to 25. By consid-
ering the clinical response to treatment and by placing that 
value in the appropriate response group (PASI 50, PASI 75, 
and PASI 90), it was possible to redistribute patients to their 
corresponding severity class for each time period.
Utilities were taken from a study by Zug and colleagues16 
and were based on the TTO method. In the base case scenario, 
it was assumed that 10% of patients with moderate psoriasis 
and 10% of patients with severe psoriasis were treated with 
intermittent etanercept. As for the distribution of patients in 
the different severity classes, it was hypothesized that 70% 
were affected by mild, 20% by moderate, and 10% by severe 
psoriasis, in accordance with expert opinion.
Costs
Only direct costs (ie, health service costs) were considered 
and they were calculated from the Italian National Health 
Service’s perspective. Regarding nonsystemic standard of 
care, costs varied from  305 to  7,960 per patient per year 
depending on the severity of psoriasis and they comprised 
expenditure for a) hospitalization; b) day-hospital admissions; 
c) specialist medical examinations; d) laboratory tests and 
instrumental investigations; e) phototherapy; or f) drug 
therapies. Expenses for items a) and b) were evaluated 
based on the national diagnosis-related group (DRG) system 
available from the Italian Ministry of Health, whereas 
items c) to f) were obtained from the “2006 National Tariff 
Nomenclator.”14
Treatment with intermittent etanercept entailed the cost 
of the drug, the fees for the physician and other medical staff. 
The price of etanercept is  4,788 per cycle, considering the 
dosage chosen (25 mg twice weekly). To evaluate medical 
staff time, it was assumed that 10% of patients received home 
visits for etanercept injections.17 It was calculated that each 
visit lasted 15 minutes on average for a total annual cost of 
Full responder (PASI > 75)
Remission
Partial responder (PASI 50−74)
Continue treatment
Non responder (PASI < 50)
Stop treatment
Etanercept intermittent
Relapse
Etanercept intermittent
Remission
Full responder (PASI > 75)
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Low responder (PASI < 75)
Stop treatment
Continue treatment
Stop treatment
Patients with moderate-severe plaque psoriasis
Figure 1 Model structure.
Abbreviation: PASi, Psoriasis Area and Severity index.ClinicoEconomics and Outcomes Research 2009:1 56
Colombo et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
58.42 per patients. Hence, total annual costs of treatment 
with etanercept are  9,725. Costs for side effects were not 
included into the model but were taken into consideration 
in the sensitivity analyses. All costs are expressed in euros 
and are updated to 2008 values according to the official 
inflation rates.18
Results
The results of our extrapolations show that treatment cost 
of moderate-to-severe plaque-type psoriasis with intermit-
tent etanercept (25 mg twice weekly) during the first year 
of treatment is nearly twice that of nonsystemic standard of 
care ( 8,528 vs  3,693); this amount is halved during the 
second year of therapy and tends to decrease constantly as a 
result of treatment discontinuation. Expenses for nonsystemic 
standard of care diminish slightly during the first year and 
then remain constant for the remaining nine years (Figure 3). 
Costs for treating psoriasis are very sensitive to the severity 
of disease. To obtain some insights on the average direct costs 
per individual over the 10-year time window, we stratified 
our patient population into two groups with different 
baseline severity: patients with moderate and severe psoriasis 
(PASI  10) and patients with severe psoriasis (PASI  20).
The results are reported in Table 1 and show that the 
average total direct costs per patient with an initial PASI 
score of 20 or higher treated with etanercept is  55,959 
over 10 years, compared with  40,051 of patients with PASI 
of 10 or higher. This relationship holds also in the case of 
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Figure 2 Percent of patients initiated on intermittent treatment with etanercept who remain on etanercept by year.
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nonsystemic therapy where expenses are higher with more 
severe forms of the disease:  50,045 and  32,441 over 10 
years, respectively (Table 1).
When ICER is considered, the situation is reversed 
in that for patients receiving intermittent therapy with 
etanercept, the additional cost per QALY gained is lower 
for individuals affected by severe (PASI  20) psoriasis 
( 25,486) compared with individuals with a moderate-and-
severe form (PASI  10) of the disease ( 33,216) (Table 1). 
Etanercept was more cost-effective in the patients with more 
severe disease, partly due to greater cost offsets and partly 
due to a greater improvement from baseline in utility, than it 
was in the patients with more moderate disease.
Sensitivity analysis
To test the robustness of the analysis, sensitivity analyses 
were carried out by varying some parameters, namely the 
cost of hospitalization, efficacy and the discounting rate. 
By increasing the cost of etanercept by 20%, patients would 
obtain ICERs of  42,216/QALY (PASI  10) and  33,968/
QALY (PASI  20). Conversely, if the cost of the biologic 
were decreased by 20%, ICERs for patients with PASI of 
10 or higher and with PASI of 20 or higher would be  24,216/
QALY and  17,004/QALY respectively. As expected, ICERs 
are higher or lower compared with the base case scenario, but 
in both cases the lower relative cost per QALY of etanercept 
is associated with more severe forms of plaque-type psoriasis, 
thus confirming the results obtained in the primary analysis. 
When all other costs are either increased or decreased by 
20%, ICERs do not differ significantly from the values 
obtained in the base case, in both groups of disease severity. 
This result may be due to patients in both etanercept and 
nonsystemic standard of care groups confronting many of 
these same costs. A similar result occurs when a single cost 
such as hospitalization is varied by 20%. All sensitivity results 
are shown in Tables 2 and 3 and in Figure 4.
Table 3 presents results in sensitivity analysis when an 
upper and lower estimate of 20% difference from the primary 
analysis for efficacy is used in both treatment options and in 
discounting. Such changes moved the ICER by 3% to 12%.
Discussion
We analyzed the cost–utility of etanercept, one of the 
biological therapies licensed in Italy for the treatment of 
moderate-to-severe plaque-type psoriasis in adults who 
failed to respond to, or who have a contraindication to, or 
are intolerant to other systemic therapy. The analysis was 
based on a Markov model that allowed us to make long-term 
extrapolations over a 10-year time horizon. Initially, direct 
costs associated with intermittent etanercept are significantly 
higher compared with nonsystemic standard of care, then 
they decrease progressively for two main reasons. First of 
all, some patients discontinue etanercept in line with the 
model’s assumptions on efficacy, as described in the section 
on Materials and methods. Secondly, due to etanercept’s 
greater efficacy, patients remain in less severe severity classes 
compared with subjects receiving nonsystemic standard of 
care, thus producing clinical and economical advantages.
Table 1 Results for different degrees of initial disease severity
Initial PASI 
score
Average total cost per patient 
in EUR (over 10 years)
Average QALYs per 
patient (over 10 years)
ICER (Incremental Cost 
Effectiveness Ratio)
Etanercept
Basal treatment
10 €40,051 
€32,441
6,778 
6,549
€33,216
Etanercept
Basal treatment
20 €55,959 
€50,045
6,332 
6,100
€25,486
Abbreviation: iCER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; PASi, psoriasis area and severity index.
Table 2 Sensitivity analysis on costs
ICER (Incremental Cost Effectiveness Ratio)
Initial PASI 
score
Etanercept 
cost +20%
Etanercept 
cost -20%
Basal treatment 
cost +20%
Basal treatment 
cost -20%
Hospitalization 
cost +20%
Hospitalization 
cost -20%
Etanercept  
Basal treatment
10 €42,216 €24,216 €32,224 €34,208 €32,384 €34,048
Etanercept  
Basal treatment
20 €33,968 €17,004 €24,211 €26,761 €24,175 €26,797
Abbreviation: iCER, incremental cost-effectiveness ratio.ClinicoEconomics and Outcomes Research 2009:1 58
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Table 3 Sensitivity analysis on efficacy
ICER (Incremental Cost Effectiveness Ratio)
Initial PASI   
score
Etanercept  
efficacy +20%
Etanercept  
efficacy 20%
Basal treatment 
efficacy +20%
Basal treatment 
efficacy -20%
Discounting 
rate 3,5%
Etanercept/Basal treatment 10 €35.931 €29.277 €34.017 €32.440 €33.192
Etanercept/Basal treatment 20 €26.235 €23.670 €26.200 €24.791 €25.537
Abbreviation: iCER, incremental cost-effectiveness ratio.
By stratifying the patient population into two groups, 
namely with moderate and severe plaque psoriasis 
(PASI  10) and severe plaque psoriasis (PASI  20), 
we obtained cost-effectiveness ratios of  33,216 and 
25,486, respectively. It is worth noting that incremental 
cost-effectiveness versus standard of care is lower with 
more severe forms of the disease and this result is in line 
with literature data. This relationship was also confirmed in 
sensitivity analyses where costs and efficacy were varied.
Our economic evaluation has some limitations. First 
of all, it is important to observe that this analysis is 
limited by the data available: literature data, such as 
efficacy, entered into the model are based on a short-term 
time-frame (about 24 months) which may be inadequate for 
modeling the treatment of a chronic disease for a longer 
time-horizon. Secondly, utility data were derived from the 
TTO questionnaires obtained from an American survey16 on 
patients with psoriasis, assuming that health state preferences 
would be similar for the Italian setting. Thirdly, costs related 
to possible adverse effects were not entered into the model 
but were only considered when sensitivity analyses were 
performed and costs were varied. The hypothesis was that 
their impact would be relatively small but this may have led 
to underestimation of costs especially for more severe cases, 
where the number of hospitalizations increases. Neither was 
mortality considered, based on the assumption that although 
it can have a major negative effect on QALYs, life span is 
generally not thought to be affected.1
To conclude, our aim was to create a health economic 
model to investigate the potential economic effect of 
intermittent etanercept compared with topical treatment, 
considering that licensed biological treatments provide a 
major advance in the treatment of plaque psoriasis though 
their use is currently restricted.
As for Italy, this is to our knowledge the first attempt to 
undertake a cost–utility analysis. Despite the limits of this 
kind of evaluation, we were able to show that the incremental 
costs per QALY gained for patients receiving intermittent 
€0
€10.000
€20.000
€30.000
€40.000
€50.000
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Etan. cost +20%
Etan. cost −20%
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Figure 4 Findings of sensitivity analysis: cost per QALY gained.
Abbreviations: QALY, quality-adjusted life-year; PASi, psoriasis area and severity index.ClinicoEconomics and Outcomes Research 2009:1
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etanercept were lower in cases with worse baseline quality 
of life and clinical severity. Though no officially established 
threshold on cost per QALY is available for Italy, our 
results ( 25,486/QALY and  33,216/QALY for etanercept) 
are lower than two commonly accepted thresholds of  36,500/
QALY19 and  60.000/QALY20 calculated by two different 
authors for the Italian setting.
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